JPRN-UMIN000008364已完成2 期
Chemotherapy with EGFR-tyrosine kinase inhibitor (EGFR-TKI) or chemotherapy alone in elderly patients with advanced NSCLC with acquired resistance to EGFR-TKI (NEJ017) - NEJ017
orth East Japan Study Group0 个研究点目标入组 100 人开始时间: 2012年7月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with severe drug allergy 2)Patients with active infection 3)Patients who uses steroids or immunosuppressant drugs 4)Patients with uncontrollable disease 5)Patients with interstitial pneumonia or pulmonary fibrosis on chest CT 6)Patients with massive pleural effusion, ascites, pericardial effusion (drainage or pleurodesis with OK432 or minocylcine are permissive.) 7)Patients who received surgery within 3 weeks or radiotherapy within 2 weeks of registration 8)History of active double cancer within 5 years 9)Patients who have the possibility of pregnancy or in lactation period 10)Patients with symptomatic brain metastases 11)HBs antigen positive 12)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
研究者
相似试验
招募中
2 期
Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment (PACE-Lung)2024-517965-18-00Goethe University Frankfurt, Goethe University Frankfurt400
招募中
2 期
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic CarcinomaCarcinoma, Adenoid CysticNCT04974866Qingdao Central Hospital20
已完成
2 期
EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual ProgressionLung AdenocarcinomaEGFR Activating MutationNCT03544814Shanghai Chest Hospital99
Unknown
3 期
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLCEGFR Gene MutationNCT02886195Fujian Cancer Hospital120
Unknown
4 期
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung CancerNon-Small-Cell Lung CancerNCT02031601Qilu Hospital of Shandong University250